Home / Health / FDA Delays Trump's Fast-Track Drugs Amid Safety Alarms
FDA Delays Trump's Fast-Track Drugs Amid Safety Alarms
15 Jan
Summary
- FDA reviewers flagged safety and efficacy concerns, causing delays.
- A patient died while taking one of the drugs under review.
- The fast-track program promised quick decisions on critical drugs.
The U.S. Food and Drug Administration (FDA) has recently delayed reviews for several drugs chosen for the Trump administration's expedited review initiative. These postponements stem from serious safety and efficacy concerns identified by FDA scientists. Notably, one drug's review was pushed back due to a patient death during its trial.
The FDA Commissioner's National Priority Voucher Program, launched in June, aimed to deliver decisions on critical drugs within one to two months, significantly faster than the standard process. However, internal documents reveal delays exceeding the promised timelines for multiple medications, including experimental treatments for rare blood disorders and type 1 diabetes.
These delays, which have not been previously reported, have sparked debate among regulatory experts. While some view the extensions as a positive sign of thorough review, others express concerns about the program potentially politicizing drug approvals and the rigorousness of expedited assessments.
